OwieClear Type 1 Diabetes Page Accuracy Review
An independent accuracy review of our type 1 diabetes page, finding the core science correct but the page too thin, and asking for hypoglycemia education, sick-day and DKA guidance, a complications section and richer technology content.
Submitted research brief - Submitted to OwieClear; written with an AI assistant - November 2026
Read this first. This document was written outside OwieClear and has not been reviewed by a clinician. We publish it so you can read the source for yourself. It is educational and is not medical advice. Where our own pages disagree with it, follow our pages, which cite their sources, and ask a healthcare professional about anything that affects your care.
What we found that needs correcting
- This review was commissioned as a check on our own work and we are publishing it unedited, including its central judgement that the page was directionally accurate but thin for a condition this demanding. That was correct. We have acted on all seven of its points in update 301, and the notes below record what changed.
- On the first point, hypoglycemia education, which the review rated the highest priority. The page now lists the warning signs, gives the rule of 15 with specific treatments, states that severe lows can cause seizure or unconsciousness, and gives the glucagon instruction including that nothing should be put into the mouth of someone who cannot swallow safely. A full deep dive covers unawareness, driving, nights and alcohol.
- On the second, DKA prevention and sick days. The page now carries the sick-day rules, with the central instruction never to stop basal insulin during illness, when to check ketones, and when to go to the emergency department. A deep dive covers why ketones form, blood ketone thresholds, the warning signs, and why repeated DKA is usually a signal about circumstances rather than knowledge.
- On the third, technology. Hybrid closed-loop systems, time in range and what sensors add are now on the page and have a deep dive of their own, including the parts that are rarely discussed: alarm fatigue, skin reactions, device failure and unequal access.
- On the fourth, complications. The page now has a complications section covering eyes, kidneys, nerves, feet and heart alongside the acute risks, with the screening schedule attached and a deep dive on what the DCCT showed about early control.
- On the fifth, the honeymoon phase. It is now explained on the page and in the staging deep dive, including that it does not mean the diabetes has gone and that insulin is reduced rather than stopped.
- On the sixth, family and genetics. The page now gives the actual family risk figures, which relatives consistently overestimate, and explains that antibody screening exists for relatives.
- On the seventh, teplizumab. The page now says what it is, that it is licensed for stage 2 disease, that it delays clinical onset by a median of around two years, and that it delays rather than prevents.
- The suggested symptom framing has been adopted in full, including the emergency line for possible DKA and the ongoing-management line for hypoglycemia.
- Two additions of our own. Adult misdiagnosis now has its own treatment on the page and in a deep dive, because roughly half of new type 1 diagnoses are in adults and being assumed to have type 2 is the most consequential error in this condition. And we have stated plainly that type 1 diabetes cannot be reversed by diet or supplements, because those claims lead to insulin being reduced and have caused deaths.
- We have also added sixteen research deep dives covering the autoimmune mechanism, staging, diagnosis, screening and delay therapy, insulin replacement, pumps and sensors, carbohydrate counting, hypoglycemia, ketones and sick days, daily life, exercise, complications, prevention research, and the discovery of insulin.
Download the PDF
Our reviewed pages on this
All source documents